BR112013015957B1 - Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit - Google Patents
Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit Download PDFInfo
- Publication number
- BR112013015957B1 BR112013015957B1 BR112013015957-0A BR112013015957A BR112013015957B1 BR 112013015957 B1 BR112013015957 B1 BR 112013015957B1 BR 112013015957 A BR112013015957 A BR 112013015957A BR 112013015957 B1 BR112013015957 B1 BR 112013015957B1
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- naltrexone
- acceptable salt
- bupropion
- binge eating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41935410P | 2010-12-03 | 2010-12-03 | |
US61/419,354 | 2010-12-03 | ||
PCT/US2011/063170 WO2012075453A1 (en) | 2010-12-03 | 2011-12-02 | Methods for reducing binge or compulsive eating |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013015957A2 BR112013015957A2 (pt) | 2019-10-29 |
BR112013015957B1 true BR112013015957B1 (pt) | 2021-07-20 |
Family
ID=46172302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013015957-0A BR112013015957B1 (pt) | 2010-12-03 | 2011-12-02 | Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit |
Country Status (26)
Country | Link |
---|---|
US (2) | US20130252995A1 (zh) |
EP (1) | EP2646011B1 (zh) |
JP (1) | JP2014508717A (zh) |
KR (1) | KR20140035319A (zh) |
CN (1) | CN103298462A (zh) |
AR (2) | AR084093A1 (zh) |
AU (3) | AU2011336298B2 (zh) |
BR (1) | BR112013015957B1 (zh) |
CA (1) | CA2819003A1 (zh) |
CL (1) | CL2013001565A1 (zh) |
CY (1) | CY1119560T1 (zh) |
DK (1) | DK2646011T3 (zh) |
ES (1) | ES2647232T3 (zh) |
HR (1) | HRP20171678T1 (zh) |
HU (1) | HUE034641T2 (zh) |
IL (1) | IL226483A0 (zh) |
LT (1) | LT2646011T (zh) |
MX (1) | MX350304B (zh) |
NO (1) | NO2646011T3 (zh) |
PL (1) | PL2646011T3 (zh) |
PT (1) | PT2646011T (zh) |
RS (1) | RS56548B1 (zh) |
RU (1) | RU2620913C2 (zh) |
SI (1) | SI2646011T1 (zh) |
TW (2) | TW201735912A (zh) |
WO (1) | WO2012075453A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
ES2761812T3 (es) | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CA2668885C (en) | 2006-11-09 | 2016-08-02 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
KR101841442B1 (ko) | 2010-01-11 | 2018-03-23 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2197250C2 (ru) * | 2000-10-30 | 2003-01-27 | Соколовский Сергей Ростиславович | Способ лечения наркоманий |
PT2316456T (pt) * | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CA2668885C (en) | 2006-11-09 | 2016-08-02 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
ATE460925T1 (de) | 2006-11-09 | 2010-04-15 | Orexigen Therapeutics Inc | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
CA2709861A1 (en) * | 2007-12-20 | 2009-07-02 | Neurosearch A/S | Pharmaceutical compositions |
AU2011326173B2 (en) * | 2010-11-08 | 2015-08-27 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
-
2011
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en active Application Filing
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Application Discontinuation
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
-
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
-
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
-
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
-
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017202793B2 (en) | Methods for Reducing Binge or Compulsive Eating | |
US11033543B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
JPH04507091A (ja) | 体重減量医薬組成物 | |
Nishioka et al. | The concept of aggressive nutrition therapy and clinical indication: A position paper | |
Lu et al. | An integrated approach to individualized optimal dose estimation of medication by means of dosing adjustment measures and Bi-Digital O-Ring Test | |
Ghai et al. | An epidemiological investigation of insomnia: A survey | |
WO2007073134A1 (es) | Composiciones farmaceuticas que comprenden sustancias inhibidoras de las lipasas intestinales combinadas con un complejo o-coordinado de dinicotinato de cromo para su uso en el tratamiento y control de la obesidad o sobrepeso | |
RU2788450C2 (ru) | Способы проведения терапии потери веса у пациентов с доминирующей депрессией | |
Montagno et al. | Pharmacy in the News | |
Gentile | Enteral nutrition as a life-saving treatment in patients with severe anorexia nervosa | |
Markowitz | Body mass index and disordered eating in adolescent females with type 1 diabetes | |
Van der Westhuizen | Obesity: evidence-based pharmacy practice | |
Liebenberg | The Lipid-Modifying Properties of VasostateTM in Males | |
Hecker | THE PCCA BLOG | |
Vansant | Share this story: RELATED ARTICLES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: NALPROPION PHARMACEUTICALS, INC. (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: NALPROPION PHARMACEUTICALS LLC (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |